Heparin control joint loratadine allergic purpura nephritis.docVIP

 PAGE \* MERGEFORMAT 11 Heparin control joint loratadine allergic purpura nephritis [Abstract] Objective To investigate the heparin control joint loratadine anaphylactoid purpura nephritis efficacy and safety. Methods The subjects were in our hospital in May 2008 -2010 hospitalized in June 116 cases of children with Henoch-Schonlein purpura were randomly divided for the treatment group and control group, treatment group was given intravenous heparin 125U +5% GNS150ml once a day; loratadine oral 7.5mg, once daily, 10 days for treatment. control group was given dexamethasone 0.25mg +5% GNS150ml infusion, 10 days for treatment. to observe the clinical efficacy and adverse effects, compared with the control group. Results The clinical symptoms and signs of renal damage was significantly improved (p lt;0.05, the total effective rate was 96.6 %, renal damage was significantly lower, only 11.7%. in the dexamethasone group 82.1% effective rate, renal damage was 37.5%. After treatment, the clinical efficacy and comparison of renal damage was significant (p lt; 0.05, no bleeding occurred. Conclusions of heparin control joint loratadine anaphylactoid purpura nephritis is safe and effective, its efficacy is superior to dexamethasone. [Keywords:] allergic purpura allergic purpura nephritis Heparin Loratadine [Abstract] Objective: To approach the effect and safety of heparin sodium combines loratadine to prevent and cure Henoch-Schonlein purpura nephritis. Methods: 116 inpatientchildren withHenoch-Schonlein purpura in May 2008 to June 2010 were divided into two groups randomly: treating group and control group, and treating group were given heparin sodium125U +5% GNS150ml, iv gtt, Loratadine, PO, qd 10d; control group were given dexametha sone0.25mg +5% GNS150ml, iv gtt, qd 10d. Observe the curative effect and adverse effect, compare it between the two groups. Results: In treating group, clinical symptom, signs and damage of nephritisimproveobviously, the to